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Abstract
The combined effects of lung tumor motion and limitations of treatment planning
system dose calculations in lung regions increases uncertainty in dose delivered to
the tumor and surrounding normal tissues in lung stereotactic body radiotherapy
(SBRT). This study investigated the effect on plan quality and accuracy when overrid-
ing treatment volume electron density values. The QUASAR phantom with modified
cork cylindrical inserts, each containing a simulated spherical tumor of 15‐mm, 22‐
mm, or 30‐mm diameter, was used to simulate lung tumor motion. Using Monaco 5.1
treatment planning software, two standard plans (50% central phase (50%) and aver-
age intensity projection (AIP)) were compared to eight electron density overridden
plans that focused on different target volumes (internal target volume (ITV), planning
target volume (PTV), and a hybrid plan (HPTV)). The target volumes were set to a
variety of electron densities between lung and water equivalence. Minimal differ-
ences were seen in the 30‐mm tumor in terms of target coverage, plan conformity,
and improved dosimetric accuracy. For the smaller tumors, a PTV override showed
improved target coverage as well as better plan conformity compared to the baseline
plans. The ITV plans showed the highest gamma pass rate agreement between treat-
ment planning system (TPS) and measured dose (P < 0.040). However, the low elec-
tron density PTV and HPTV plans also showed improved gamma pass rates
(P < 0.035, P < 0.011). Low‐density PTV overrides improved the plan quality and
accuracy for tumor diameters less than 22 mm only. Although an ITV override gener-
ated the most significant increase in accuracy, the low‐density PTV plans had the
additional benefit of plan quality improvement. Although this study and others
agreed that density overrides improve the treatment of SBRT, the optimal density
override and the conditions under which it should be applied were found to be
department specific, due to variations in commissioning and calculation methods.
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1 | INTRODUCTION
Lung Cancer is one of the world's most commonly diagnosed cancer
types, as well as the most common cause of cancer death with an esti-
mated 1.6 million deaths worldwide per year.1 Non‐small cell lung can-
cer (NSCLC) contributes to approximately 85% of all lung cancers.2
For patients whom surgery is not an option, conventional or
stereotactic radiotherapy is frequently used.3,4 One of the main toxi-
cities stemming from radiation therapy in NSCLC is Radiation Pneu-
monitis (RP).5,6 The use of stereotactic body radiotherapy (SBRT) to
reduce the Planned Target Volume (PTV) margin and increase PTV
edge dose gradients can improve local control and reduce the
chance of toxicities such as RP.7
One of the issues associated with treating lung cancer with
radiotherapy is motion of the tumor caused by patient breathing.
In SBRT, this issue becomes an even greater challenge due to the
addition of the smaller expansion of the PTV around the Internal
Target Volume (ITV), with a steep dose gradient beyond this target
volume.8 The most common technique for managing temporal
tumor variation is four‐dimensional imaging, including respiration‐
correlated 4‐Dimensional CT (4DCT) scanning,9 however, this can
result in motion artifacts.10 Artifacts can be caused by irregular
breathing traces, for example, coughing or patient motion during
the scanning process.11
The presence of inhomogeneous media can also affect dose cal-
culation accuracy. Several studies have examined the impact of dif-
ferent dose calculation algorithms on dose delivered to
inhomogeneous media, in particular lung.12–15 It is recommended
that collapsed cone convolution (CCC) algorithms be used when
complex algorithms such as Monte Carlo or Acuros XB (Varian Medi-
cal Systems, Palo Alto, CA) are not readily available.12,13 One issue
with CCC algorithms is that the model is unable to accurately calcu-
late dose at the interface between lung and tumor.12 This is due to
the assumption of transient charged particle equilibrium (TCPE)
occurring at the tumor–lung interface not being true, and CCC algo-
rithms cannot accurately model this effect.15 These errors have been
shown to increase with smaller treatment volumes, where the ratio
of tumor–lung interface surface area to tumor volume increases with
decreasing target volume.12
During treatment, as the GTV moves through the ITV as defined
by the 4DCT scan, the dose to the tumor will change compared to
the treatment plan. As there is preferential dose buildup in higher
density areas, as the GTV moves to a region of the ITV that is
underdosed on the treatment plan, the GTV will receive a larger
dose than expected.14,16
One method to overcome the issues associated with inhomo-
geneity corrections in lung and tumor motion is to override the elec-
tron densities of the ITV/PTV.17–19 A study by Fu et al.17 devised a
method for overriding the density of the PTV to 0.8 g/cm3 to reduce
the planned MU while still delivering sufficient dose to the tumor
for SBRT lung planning. Wiant et al.18 compared the use of free‐
breathing CT scans, time average scans, and ITV/PTV tissue‐density
overridden scans for lung SBRT to evaluate the accuracy of each
method for predicting dose deposition in lung tissue. Accuracy was
assessed from measurements using Gafchromic film in a QUASAR
phantom.18 A further study by Wiant et al.19 looked at volumetric
modulated arc therapy (VMAT) plans, and introduced a hybrid over-
ride with the ITV set to tumor density and PTV‐ITV set to an inter-
mediate density.
The studies by Wiant et al.18,19 were performed using the Eclipse
planning system, and the method has not currently been extended
to any other dose calculating algorithms. Also any implications due
to tumors size or overriding the density of the PTV to a variety of
low densities between lung and water have not been investigated.
This study will look into quantifying the effect of density overrides
to establish a trend based upon the relative sizes of the ITV and
PTV.
2 | METHODS
2.A | Phantom study
To assess the impact of various density overrides on SBRT lung
plans, a phantom study was conducted using the Elekta Synergy
Linac and Monaco 5.1 TPS. A QUASAR Programmable Respiratory
Motion Phantom (Modus Medical Devices Inc., London, ON, Canada)
with modified inserts was used to simulate the craniocaudal motion
of a lung tumor inside a SBRT patient.
A study by Chang et al.20 compared the use of several lung
substitute materials to reference lung material as listed in ICRU‐
44. From this study, composition cork was found to be an accept-
able lung substitute based on physical and dosimetric properties.
QUASAR‐compatible inserts were designed and manufactured in‐
house (Fig. 1). These included spherical PMMA tumor lesions with
a density of 1.18 g/cm−3 and diameters of 15 mm, 22 mm, and
30 mm, corresponding to a range applicable to the lung tumor
sizes treated clinically. Two types of inserts were designed, one
for point dose measurements with a CC13 chamber and one for
Gafchromic film.
A Siemens SOMATOM Definition CT scanner (Siemens Health-
care Limited) was used to acquire the 4DCT scans with the QUA-
SAR phantom set to a 4.0‐s breathing period and 15‐mm motion
amplitude. The respiratory waveform was simultaneously recorded
with the Varian Real‐time Position Management (RPM) system. For
each of the different cork inserts, the reconstruction process gen-
erated the average intensity projection (AIP) and a dataset contain-
ing each of the 10 respiratory phases from which the maximum
intensity projection (MIP) was generated. The three required image
datasets (AIP, MIP, and a 50% central phase dataset) were
exported to the TPS.
The contouring of the two target volumes, the ITV and the PTV,
was completed using the Monaco 5.1 TPS (Elekta, Inc) and utilized
the MIP of each of the 4D CT scans for the different cork inserts.
The PTV expansion was 1 cm in the superior/inferior direction and
0.5 cm in the axial plane. The contours were applied to each of the
AIP and 50% central phase datasets for each insert.
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A 3DCRT SBRT plan was developed on the 50% central phase
datasets, with a prescription of 48 Gy in four fractions. Beam
weightings were manually optimized using the van't Reit formula for
Conformity Index.21
Three different electron density (ED) values were investigated cor-
responding to different proportions of lung and water. An average lung
ED of 0.300 was used to determine the ED values for the different
proportions. This value was consistent to the values seen clinically in
our department, rounded to one significant figure. An average water
ED of 1.000 was used. The overrides corresponded to 75% lung mate-
rial and 25% water (ED = 0.475), 50% lung material and 50% water
(ED = 0.650), and 25% lung material and 75% water (ED = 0.825).
These were applied to the PTV, with or without the ITV set to an ED
of 1.000 to form a hybrid plan. In total, eight override datasets were
generated for each plan, and compared to the AIP and 50% central
phase plans (Table 1). No beam weighting changes were applied with
each override. The dose was rescaled to cover the PTV volume with
the prescription dose set to the relative isoline of 80%.
2.B | Plan quality and coverage
To assess the relative coverage of each override plan compared to
the baseline plans (AIP and 50% central phase), five PTV coverage
metrics were assessed. This including the Mean Dose (Gy), Maximum
Dose (Gy), Minimum Dose (Gy), D90, and D95. As these plans were
forward planned using the collapsed cone algorithm, the Maximum
and Minimum Doses (Gy) refers to dose at a point.
For Conformity and Heterogeneity, three Conformity Indices (CI)
were used: van't Reits CI, CI(100%), and CI(50%). One metric for
Heterogeneity Index (HI) was used.
2.B.1 | Conformity and heterogeneity indices
Monaco 5.1 uses the van't Riet formula for CI, which defines three
volumes: the volume of the target receiving the prescribed dose
F I G . 1 . Above: The QUASARTM
Programmable Respiratory Motion
Phantom used at Christchurch Hospital,
with a cedar ion chamber insert on the left
and a cedar filler insert on the right.
Below: The Cork‐based QUASAR‐
compatible inserts. Left: 30‐mm CC13
insert. Right: 30‐mm film insert.
TAB L E 1 The Monaco 5.1 treatment plans investigated for each
tumor size, and the corresponding relative electron density overrides
applied.
Plan type ITV ED PTV ED










ED, Electron Density (relative to water); 50% Phase, central phase of
tumor motion treatment plan; AIP, Average Intensity Projection treat-
ment plan; HPTV, Hybrid PTV overridden plan.
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For CI(100%) and CI(50%), the CI(X%)‐type metrics indicated the
ratio of the percentage (x) isodose volume (VX%) to the target vol-




The Heterogeneity Index (HI) was also directly calculated from
the DVH statistics. To calculate HI, the High Dose Reference value
(HDR) and the Minimum Dose Reference value (MDR) were used to
calculate Dx%, the dose that covers x% of the tissue. The standard
Monaco 5.1 values for HDR and MDR were also used, correspond-




2.C | Dose verification
Two verification methods were used to compare the accuracy of the
treatment plans: Ion Chamber Point Dose Measurements and EBT3
Gafchromic Film Dosimetry.
2.C.1 | Ion chamber point dose measurements
The point dosemeasurements weremadewith a 0.13‐cc IBADosimetry
compact air ionization chamber (CC13). To compare the average charge
collected by the ion chamber in the center of the tumor volume in the
cork insert to the expected mean dose calculated by the TPS, a correc-
tion needed to be applied to the statistics reported by the TPS. This is
due to the fact that the chamber remains fixed inside the tumor insert,
but it moves relative to the PTV.
This results in the total dose being measured as an average
across the volume that the active part of the ion chamber covers. As
the amplitude of motion and the dimensions of the ion chamber cav-
ity are both known, the active volume of the chamber was con-
toured as a structure in Monaco and the mean dose in Gy compared
to that measured by the ion chamber.
2.C.2 | EBT3 gafchromic film dosimetry
EBT3 film was used in conjunction with the SNC Patient Film Analy-
sis software (V6.6, Sun Nuclear Corporation) and an Epson Expres-
sion 11000XL scanner. As the tumor lesion moves inside the PTV on
the TPS a reference frame correction was applied to each of the
TPS Dose Planes. However, for the film measurement the film was
fixed relative to the motion of the cork insert, and therefore the
frame of reference coincides with the position of the tumor. A time‐
weighted average correction was applied to each dose value in the
TPS dose plane. As the motion of the GTV was sinusoidal with a
fixed amplitude and period, the dose values only needed to be
corrected in the direction of motion.
3 | RESULTS
The effectiveness of each density override was assessed in two
ways, including comparing the plan quality in the treatment planning
system and the measurable aspects of the plan with point dose and
radiochromatic film measurements.
3.A | Plan quality and coverage
Comparison of the baseline plans (AIP and 50% central phase) to the
density overridden plans for the 15‐mm insert shows that in every
case the target coverage was at worst unchanged and mostly
TAB L E 2 The target coverage DVH metrics and PTV conformity and heterogeneity metrics for a range of standard and electron density






HIMean Max Min D90 D95 50% 100% van't Reits
50% Phase 12.7 15.0 9.4 11.6 11.2 1469.9 4.87 0.87 0.76 1.27
AIP 13.5 15.4 10.0 12.3 11.9 1548.5 5.36 1.16 0.78 1.26
ITV = 1.000 13.1 15.0 9.4 11.6 11.3 1460.2 4.82 0.89 0.79 1.31
PTV = 0.475 14.1 15.2 10.8 13.1 12.7 1449.6 4.79 1.18 0.86 1.18
PTV = 0.650 13.9 15.1 10.4 12.7 12.4 1494.5 5.08 1.18 0.83 1.20
PTV = 0.825 13.9 15.1 10.4 12.8 12.4 1457.8 4.87 1.15 0.85 1.20
PTV = 1.000 14.1 15.1 10.6 13.0 12.6 1447.7 4.80 1.15 0.86 1.19
HPTV = 0.475 13.6 15.0 10.1 12.4 12.0 1453.4 4.82 1.07 0.86 1.24
HPTV = 0.650 13.9 15.1 10.4 12.8 12.4 1450.7 4.82 1.13 0.86 1.21
HPTV = 0.825 14.4 15.1 10.6 13.0 12.6 1450.0 4.80 1.16 0.86 1.19
Plan Type format, ITV = 1.000 indicates the ITV is set to a relative electron density of 1.000.
CI, Conformity Index (50% isodose, 100% isodose, van't Reits formula); HI, Heterogeneity Index; 50% Phase, central phase of tumor motion treatment
plan; AIP, Average Intensity Projection treatment plan; HPTV, Hybrid PTV overridden plan.
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improved (Table 2). Aside from the ITV plan, the D95 value
increased by 1.2 ± 0.4 Gy when compared to the 50% central phase
plan. Consistent with the target coverage metrics, the ITV plan
showed the least amount of difference between it and the 50% cen-
tral phase and AIP plans in terms of the CI and HI.
For the 22‐mm insert, less variation can be seen between the
different density overrides compared to the 15‐mm insert (Table 3).
For the PTV and HPTV plans, the D95 value increased by
1.1 ± 0.4 Gy when compared to the 50% central phase plan. Higher
density overrides, specifically the HPTV = 0.475 plan, displayed the
best CI and HI results.
For the 30‐mm insert, the average PTV and HPTV plans D95
value increased by 0.8 ± 0.3 Gy when compared to the 50% central
phase plan (Table 4). The mean, minimum, and maximum doses
showed less of an improvement as the insert size increased from 15
mm to 30 mm. No statistically significant difference was seen
between CI (van't Riet) results (P < 0.06). The impact of density
overrides is limited for large tumor volumes.
3.B | Plan verification
3.B.1 | Point dose measurements
The majority of the point dose measurements were within the clini-
cally accepted tolerance of ±3% compared to the dose calculated by
the TPS. For each result, a Student's t test was performed to com-
pare the statistical significance of the ED override results as com-
pared to the baseline plan (50% central phase).
For the 15‐mm insert, all ED overridden plans showed a signifi-
cant (P < 0.05) difference to the 50% central phase plan (Fig. 2). The
largest percentage dose differences were for the 50% central phase
TAB L E 3 The target coverage DVH metrics and PTV conformity and heterogeneity metrics for a range of standard and electron density





HIMean Max Min D90 D95 50% 100% van't Reits
50% Phase 13.2 15.1 9.6 12.0 11.5 1435.3 4.37 1.00 0.80 1.28
AIP 13.5 15.2 9.7 12.2 11.7 1454.2 4.47 1.08 0.80 1.28
ITV = 1.000 13.5 15.3 9.6 12.0 11.6 1436.1 4.37 1.02 0.81 1.30
PTV = 0.475 14.0 15.1 10.2 12.9 12.4 1450.4 4.47 1.18 0.82 1.21
PTV = 0.650 14.1 15.2 10.3 13.0 12.6 1429.2 4.36 1.17 0.84 1.20
PTV = 0.825 14.3 15.4 10.4 13.2 12.8 1430.8 4.35 1.18 0.84 1.19
PTV = 1.000 14.4 15.5 10.7 13.3 12.9 1440.8 4.38 1.21 0.82 1.18
HPTV = 0.475 14.0 15.3 10.2 12.7 12.3 1436.4 4.38 1.14 0.84 1.23
HPTV = 0.650 14.2 15.4 10.4 13.0 12.6 1437.4 4.38 1.18 0.84 1.21
HPTV = 0.825 14.3 15.4 10.6 13.2 12.8 1439.1 4.38 1.20 0.83 1.19
Plan Type format, ITV = 1.000 indicates the ITV is set to a relative electron density of 1.000.
CI, Conformity Index (50% isodose, 100% isodose, van't Reits formula); HI, Heterogeneity Index; 50% Phase, central phase of tumor motion treatment
plan; AIP, Average Intensity Projection treatment plan; HPTV, Hybrid PTV overridden plan.
TAB L E 4 The target coverage DVH metrics and PTV conformity and heterogeneity metrics for a range of standard and electron density






HIMean Max Min D90 D95 50% 100% van't Reits
50% Phase 13.8 15.3 9.6 12.6 12.3 1414.1 4.64 1.22 0.80 1.22
AIP 13.8 15.4 9.5 12.6 12.2 1399.9 4.53 1.19 0.81 1.24
ITV = 1.000 13.9 15.5 9.6 12.6 12.2 1403.6 4.57 1.20 0.81 1.24
PTV = 0.475 14.5 15.7 10.2 13.6 13.3 1410.3 4.56 1.31 0.78 1.16
PTV = 0.650 14.2 15.3 9.9 13.2 12.9 1406.1 4.62 1.28 0.78 1.17
PTV = 0.825 14.3 15.4 9.9 13.4 13.0 1392.2 4.53 1.27 0.79 1.17
PTV = 1.000 14.4 15.6 10.1 13.5 13.2 1398.0 4.53 1.28 0.79 1.16
HPTV = 0.475 14.2 15.5 9.9 13.1 12.8 1405.0 4.57 1.26 0.79 1.20
HPTV = 0.650 14.4 15.6 10.0 13.4 13.1 1406.5 4.57 1.29 0.78 1.17
HPTV = 0.825 14.5 15.7 10.2 13.6 13.2 1408.4 4.56 1.30 0.78 1.16
Plan Type format, ITV = 1.000 indicates the ITV is set to a relative electron density of 1.000.
CI, Conformity Index (50% isodose, 100% isodose, van't Reits formula); HI, Heterogeneity Index; 50% Phase, central phase of tumor motion treatment
plan; AIP, Average Intensity Projection treatment plan; HPTV, Hybrid PTV overridden plan.
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and AIP plans. A positive trend was displayed between percentage
difference and total MU (R2 = 0.992).
For the 22‐mm insert, the best‐performing ED overrides were
the ITV = 1.00 plan and PTV = 1.00 plan (P < 0.003, P < 0.002). The
positive trend that was previously seen in the 15‐mm result
remained between the percentage difference and total MU
(R2 = 0.9532), however, the correlation was weaker.
For the 30‐mm insert, there was no density overridden plan
that showed a statistically significant improvement over the original
plans (average P < 0.232). The positive trend seen between the
percentage difference and total MU was not significant
(R2 = 0.3051). As there was limited benefit seen in the TPS and
point dose results, film work was not completed for the 30‐mm
tumor insert.
3.B.2 | Gafchromic film
Three absolute dose gamma analysis results were obtained (Criteria
of 1%/1 mm, 2%/2 mm, and 3%/3 mm) across two dose threshold
levels (10% and 40%). The plans that were most effective in the
F I G . 2 . The difference between the average doses to the ion chamber structure reported by Monaco and the measured dose to the ion
chamber, for each of the baseline and density overridden plans for the cork inserts. (a) Percentage Difference, 15‐mm insert, (b) MU difference,
15‐mm insert, (c) Percentage Difference, 22‐mm insert, (d) MU difference, 22‐mm insert, (e) Percentage Difference, 30‐mm insert, and (f) MU
difference, 30‐mm insert.
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ion chamber measurements were repeated to decrease the amount
of film required. The HPTV = 0.650 plan was used as there was
minimal difference shown in the ion chamber measurements
between HPTV plans. Forty percent was chosen to minimize the
effect of the sudden dose difference at the edge of the film. For
the 15‐mm insert, the 50% central phase plan was shown to have
the lowest mean gamma pass rates across all criteria.
The best‐performing plan was the ITV override, which showed
a 3%, 3‐mm pass rate of 92.7% for the 10% threshold, and
99.7% for the 40% threshold (Fig. 3). For the gamma criterion 2%/
2 mm and 3%/3 mm, the ITV, PTV = 0.475, and HPTV = 0.650
plans all showed significant differences to the baseline plans
(P < 0.011).
For the 22‐mm insert, the best‐performing plan was the ITV
override, which showed a 3%, 3‐mm pass rate of 90.2% for the 10%
threshold, and 94.7% for the 40% threshold gamma criteria. How-
ever, for the 10% TH gamma criteria, no plans showed a consistent
significant difference to the baseline plan.
4 | DISCUSSION
The key motivation for exploring the effect of ED overrides was to
improve the treatment of lung cancer with SBRT. This can be
achieved in two different ways: improving the quality of the
treatment plan, in terms of target coverage and conformity, and
improving the accuracy of the treatment delivery.
Overriding the ED of a target volume to a water‐equivalent ED
is associated with better target coverage due to the fact that the
CCC algorithm accounts for inhomogenieties by scaling dose kernels
by the relative electron densities.22,23 Previous studies have shown
that for the CCC algorithm, a lower lung ED is associated with a
reduced medium target dose.24 This is consistent with results seen
for the PTV and HPTV overrides. Across all inserts, the planning aim
of 95% of the PTV volume receiving the prescribed dose of 12 Gy
per fraction was achieved. In addition, none of these plans achieved
unacceptably high maximum dose values.
The ideal CI value is 1.0, whereas an acceptable HI is anything
<2.0 based on the Radiation Therapy Oncology Group (RTOG)
guidelines for SBRT. For all plans, the HI was found to be less than
2. This was expected as there were no irregular shapes in this study
or OARs to avoid. Therefore, delivering a homogeneous dose to the
PTV was less of an issue. Varying levels of agreement were seen in
the ten plans investigated for the 15‐mm, 22‐mm, and 30‐mm
inserts. While the 15‐mm and 22‐mm results showed positive corre-
lation between the prescribed MU and the dose measured by the
ion chamber, the same cannot be said for the 30‐mm insert. While
there was an improvement in dosimetric accuracy seen using plans
other than the 50% central phase plan, all results were within 1% of
the expected dose, well below the acceptable clinical limit of 2%.
F I G . 3 . The mean gamma pass rates (%) and range (±%) between the Gafchromic film and TPS dose distributions for the (a) 10% Threshold,
15‐mm tumor insert, (b) 40% Threshold, 15‐mm tumor insert, (c) 10% Threshold, 22‐mm tumor insert, and (d) 40% Threshold, 22‐mm tumor
insert.
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There is a limited application for applying density overrides to large
tumors.
The planning system performs adequately for calculating dose to
large tumors, where the effect of the uncertainty of heterogeneity
accounting algorithms is limited. Little difference was seen for the
15‐mm and 22‐mm inserts for the higher density range of overrides.
Less fluence would be required in higher densities to generate the
same desired dose coverage, resulting in fewer MU being delivered.
Although the ion chamber measurements are useful in terms of abso-
lute dose, there is limited value to the ion chamber results as the dose
measured is for only a small portion of the ITV. For both the 15‐mm
and 22‐mm results, the ITV plan showed the high gamma pass rates
for both the 2%/2 mm and 3%/3 mm criteria. Profiles through the cen-
ter of the tumor confirm improved agreement between the ITV TPS
dose plane and measured film dose plane.
When the density of the ITV or PTV is overridden closer to the
ED of the GTV, less fluence is required to deliver the prescribed
dose as conformal dose deposition is more achievable in higher ED
volumes. The lower fluence results in a reduction in the total MU
prescribed when all other beam parameters are kept constant.
When this plan is delivered, however, regardless of the position of
the GTV inside the ITV, a higher proportion of the energy fluence will
be deposited inside the higher electron density tumor as compared to
the surrounding lung material. As the tumor moves within the ITV, the
result is a higher dose overall to the ITV. As the baseline 50% central
phase plan is unable to predict this smearing out effect, the measured
dose in the center of the ITV will be higher than expected, a result that
was consistently seen in both the ion chamber and film measurements.
The impact of the dose smearing effect is not only seen in the ITV
plan, but the lower density PTV and HPTV plans as well.
Previously published work most comparable to this study is the
study by Wiant et al.19 In their study, a large diameter tumor object
was used, and the CI and mean dose values were all approximately
the same, with the only significant difference occurring with the
maximum dose to the PTV. The ITV plan showed the greatest
increase in maximum dose compared to the 50% central phase plan,
whereas the PTV and hybrid plans showed minimal differences. This
is not consistent with the plan quality results seen in this study. A
reason for the variation between results may stem from the differ-
ences between the two planning systems and the operation of the
heterogeneity accounting algorithms.
In both studies, density overrides were shown to improve dosi-
metric accuracy, but in this study density overrides were shown to be
clinically beneficial for tumors less than 22 mm. An additional study
into the mid‐sized range around 22 mm would be beneficial. Applying
an established Lung SBRT planning protocol to a small selection of
override options is necessary to determine the clinic‐specific best fit.
5 | CONCLUSION
No significant statistical difference was seen between the 50% cen-
tral phase and AIP plans. A trend was demonstrated where, for
smaller tumors (<22‐mm diameter), the geometric and dosimetric
dose coverage and conformity improved when a PTV override was
applied. For larger tumors (>22‐mm diameter), minimal differences
were seen in terms of plan quality and accuracy, suggesting the
results are equipment specific. Improvements to dosimetric accuracy
were seen as the tumor size decreased. The results established in
this study suggest a valid method for improving outcomes to
patients with NSCLC treated with SBRT, particularly for small tumors
where dosimetric as well as geometric accuracy is a greater concern.
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